Who will win Covid-19 vaccine race?

Who will win Covid-19 vaccine race?

2020-10-13 • Updated

What happened?

Goldman Sachs claimed that vaccine developments tend to have more impact on the overall sentiment than even election results or Q3 earnings. We have had already a chance to observe how recent negative news weighed on the market sentiment. Johnson & Johnson announced that it has temporarily stopped the Covid-19 vaccine trials because of the unexplained illness of one participant. As a result, the market sentiment deteriorated, and the safe-haven US dollar rose today. However, the nature of the illness hasn’t been yet defined: a special committee is trying to find it out.

Actually, it has been the second-largest setback in the vaccine race so far. AstraZeneca halted human trials for a similar reason: a patient had an adverse reaction. Trials have been resumed in the UK, Brazil, India, and South Africa, while it remains on hold in the US as the Food and Drug Administration has been still investigating that case.

High-potential companies

Both AstraZeneca and Johnson & Johnson have created adenovirus-based vaccines. So, perhaps, biotech companies, which use other technologies will have a boost. For instance, Moderna is working on a vaccine, based on the technique of using messenger ribonucleic acid (mRNA). It is said that this technique has more advantages than traditional drug development by medical and manufacturing reasons.

By the way, BioNTech uses the same mRNA technique. Pfizer and BioNTech are creating the vaccine in collaboration, and two companies have announced that their vaccine has been accepted for a rolling review by Health Canada. It looks like Pfizer and BioNTech have all chances to win this rally. Don’t you think?

Forecasts from Goldman Sachs

Goldman Sachs gives the 71% of probability that the vaccine will be available for widespread distribution by the first quarter of 2021. Notably, the bank upgraded its forecasts from 39%, which it gave in August. Elsewhere, Goldman wrote in a note to its clients that it expects strong growth in such sectors as healthcare, consumer staples, and information tech companies. At the same time, the energy and industrials sectors are predicted to slump.

Technical tips

Pfizer is edging higher. It approaches the intersection of the 200-week moving average and the strong resistance level of $37.25, which it has failed to break in previous years. That’ why we can expect some sell-off around this area. Once the breakout happens, it will encourage buyers, and the price may surge to the recent high of $39.00. On the flip side, there is a 7-months support line which constrains the price to fall beyond. The move below September’s dips of $36.00 will push the price lower to the next support of $34.00.


Just look at great BioNTech’s performance. In comparison with other biotech giants as Pfizer, it’s a young company, but it has managed to rise enormously so far. BioNTech made its US stock market initial public offering last October 15, and it increased its value so much that it has been included in Nasdaq. The move above March’s high of $95.00 will drive the price to the record high of $105.00. Support levels are $76.00 and 70.00.


What should you do for trading BioNTech and Pfizer?

Trading stocks with FBS is easy. Follow the simple steps described below.

  1. First of all, be sure you’ve downloaded Metatrader 5. FBS allows you to trade stocks only through this software.
  2. Open the MT5 account in your personal area.
  3. Reveal all trading instruments by clicking “show all” at the “Market Watch” window.
  4. Start trading!



S&P in the Сrosshairs
S&P in the Сrosshairs

Institutional investors speak about further growth in the stock market. In the exact market that has doubled since COVID-19 and doesn’t plan to stop. Is it possible?

Latest news

Will USDJPY slide lower in 2023?
Will USDJPY slide lower in 2023?

Last year was tough for the Japanese yen. USDJPY gained more than 30% over 2022, striking above 150 in October. While anticipation of slower Fed rate hikes pulled the pair below the 130 level at the start of 2023, the speculations over the destiny of BOJ’s yield control policy grabbed the attention of the Japanese assets in the middle of January. What lies ahead for traders of the Japanese yen?

BoC Rates Could Alter The Trend on USDCAD and others
BoC Rates Could Alter The Trend on USDCAD and others

Today, at 5:00 pm (GMT +2), the Bank of Canada will publish the Overnight Rate, which represents short-term interest rates, and is pivotal to the overall pricing of the Canadian Dollar in the global markets. Let's look at how the markets are faring ahead of the BoC rates release.

MSFT faces gloomy forecasts ahead of earnings report
MSFT faces gloomy forecasts ahead of earnings report

In a call scheduled for January 25, 00:30 am GMT+2, Microsoft will publish the company's earnings for the final quarter of 2022 and comment on the results, projections, and outlook for the nearest future of the company.

Deposit with your local payment systems

Feel the Team Spirit

Data collection notice

FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.


A manager will call you shortly.

Change number

Your request is accepted.

A manager will call you shortly.

Next callback request for this phone number
will be available in

If you have an urgent issue please contact us via
Live chat

Internal error. Please try again later

Don’t waste your time – keep track of how NFP affects the US dollar and profit!

Beginner Forex book

Beginner Forex book will guide you through the world of trading.

Beginner Forex book

The most important things to start trading
Enter your e-mail, and we will send you a free Beginner Forex book

Thank you!

We've emailed a special link to your e-mail.
Click the link to confirm your address and get Beginner Forex book for free.

You are using an older version of your browser.

Update it to the latest version or try another one for a safer, more comfortable and productive trading experience.

Safari Chrome Firefox Opera